Skip to main content

Heat Shock Protein 90α Provides an Effective and Novel Diagnosis Strategy for Nasopharyngeal Carcinoma

Abstract

Introduction

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated tumor occurring in southeastern Asia. Due to insidious onset, it is difficult to diagnose NPC from clinical symptoms. Thus, there is an urgent need for non-invasive, high-performance biomarkers to aid the clinical diagnosis of NPC. Heat shock protein 90α (HSP90α) is an important member of the heat shock protein family that significantly increases under stress conditions such as oxidation and tumors. This is the first investigation of the role of Hsp90α in the diagnosis and progress of NPC.

Methods

Plasma Hsp90α was detected by ELISA in 196 newly diagnosed NPC patients, 76 corresponding post-treatment NPC patients, 230 VCA-IgA-positive normal subjects and 106 healthy controls.

Results

(1) The level of Hsp90α in plasma of 196 NPC patients was (212.16 ± 144.32) ng/ml, which was significantly higher than that in VCA-IgA-positive normal subjects (68.12 ± 64.94 ng/ml, P < 0.001) and healthy controls (35.87 ± 17.47 ng/ml, P < 0.001); (2) the levels of Hsp90α in patients with NPC in the early stage (I + II), stage III and stage IV were significantly different (159.69 ± 117.12 pg/ml vs. 195.24 ± 126.38 pg/ml vs. 250.85 ± 164.66 pg/ml, P = 0.018 and P = 0.029, respectively). The level of Hsp90α in plasma in patients with metastasis of NPC and those without metastasis was significantly different (P < 0.001); (3) Hsp90α is closely related to EBV DNA levels, but not to the VCA-IgA titer and EA-IgA titer; (4) the levels of Hsp90α in plasma of patients with NPC before and after treatment were significantly different (212.16 ± 144.32 pg/ml vs. 62.36 ± 34.04 pg/ml, P < 0.001); (5) the ROC curves demonstrated that the sensitivity of plasma Hsp90α in distinguishing NPC patients from healthy controls was 74.50% and the specificity was 99.10% (AUC = 0.931, 95% CI 0.903–0.958).

Conclusion

The study found that the plasma HSP90α level is closely related to the clinical stage, metastasis and therapeutic effect of NPC. HSP90α may serve as a new biomarker for diagnosis and treatment of NPC.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  2. Chen YP, Chan A, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64–80.

    Article  Google Scholar 

  3. Liu Z, Ji MF, Huang QH, Fang F, Liu Q, Jia WH, Guo X, Xie SH, Chen F, Liu Y, Mo HY, Liu WL, Yu YL, Cheng WM, Yang YY, Wu BH, Wei KR, Ling W, Lin X, Lin EH, Ye W, Hong MH, Zeng YX, Cao SM. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China. Am J Epidemiol. 2013;177:242–50.

    Article  Google Scholar 

  4. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761–72.

    CAS  Article  Google Scholar 

  5. Thomas M, Harrell JM, Morishima Y, Peng HM, Pratt WB, Lieberman AP. Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum Mol Genet. 2006;15:1876–83.

    CAS  Article  Google Scholar 

  6. Peterson LB, Blagg BS. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem. 2009;1:267–83.

    CAS  Article  Google Scholar 

  7. Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ, Hsu WL, Sun B, Hsu MM, Chen IH, Chen JY, Yang CS, Mittl BL, Chou SP, Ruggles DD, Goldstein AM, Hildesheim A. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer. 2004;111:117–23.

    CAS  Article  Google Scholar 

  8. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z, Meng NN. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985;36:545–7.

    CAS  Article  Google Scholar 

  9. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS, Su GR. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer. 1982;29:139–41.

    CAS  Article  Google Scholar 

  10. Zeng Y, Zhong JM, Li LY, Wang PZ, Tang H, Ma YR, Zhu JS, Pan WJ, Liu YX, Wei ZN, Et A. Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology. 1983;20:190–4.

    CAS  Article  Google Scholar 

  11. Han BL, Xu XY, Zhang CZ, Wu JJ, Han CF, Wang H, Wang X, Wang GS, Yang SJ, Xie Y. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev. 2012;13:2577–81.

    Article  Google Scholar 

  12. Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G, Luo Y. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci USA. 2009;106:21288–93.

    CAS  Article  Google Scholar 

  13. Shi Y, Liu X, Lou J, Han X, Zhang L, Wang Q, Li B, Dong M, Zhang Y. Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses. Clin Cancer Res. 2014;20:6016–22.

    CAS  Article  Google Scholar 

  14. Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S, Carreras C, Neckers L. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene. 2008;27:2478–87.

    CAS  Article  Google Scholar 

  15. Chen K, Wang HQ, Zhang Z, Lu XZ, Ouyang D. Correlation of heat shock protein 70 expression in nasopharyngeal carcinoma to immunoglobin a against viral capsid antigen of Epstein-Barr virus in sera and its clinical significance. Ai Zheng. 2008;27:650–3.

    CAS  PubMed  Google Scholar 

  16. Feng J, Zhan Y, Zhang Y, Zheng H, Wang W, Fan S. Increased expression of heat shock protein (HSP) 10 and HSP70 correlates with poor prognosis of nasopharyngeal carcinoma. Cancer Manag Res. 2019;11:8219–27.

    CAS  Article  Google Scholar 

  17. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene. 2004;23:2907–18.

    CAS  Article  Google Scholar 

  18. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol. 2003;15:419–24.

    CAS  Article  Google Scholar 

  19. Pratt WB, Galigniana MD, Harrell JM, DeFranco DB. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal. 2004;16:857–72.

    CAS  Article  Google Scholar 

  20. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol. 2004;6:507–14.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank the staff of the biochemical laboratory of Sun Yat-sen University Cancer Center who provided various biochemical markers and all of the staff who supported our study.

Funding

This work was supported by grants from the National Natural Science Foundation of China (no. 81871711). The journal’s Rapid Service Fee was funded by the authors.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

All named authors (Minjie Mao, Xueping Wang, Hui Sheng, Huilan Li, Wen Liu, Runkun Ha, Wangrong Wen and Wanli Liu) have nothing to disclose.

Compliance with Ethics Guidelines

The Institute Research Ethics Committee of the Sun Yat-Sen University Cancer Center, Guangzhou, China, approved this study (GZR2018-197). All patients provided written informed consent. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.

Data Availability

The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (www.researchdata.org.cn), with the approval RDD number as RDDA2020001725.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Wangrong Wen or Wanli Liu.

Additional information

Wanli Liu and Wangrong Wen are both corresponding authors.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mao, M., Wang, X., Sheng, H. et al. Heat Shock Protein 90α Provides an Effective and Novel Diagnosis Strategy for Nasopharyngeal Carcinoma. Adv Ther 38, 413–422 (2021). https://doi.org/10.1007/s12325-020-01518-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-020-01518-4

Keywords

  • Biomarker
  • Diagnosis
  • Heat shock protein 90α
  • Nasopharyngeal carcinoma